一个基于贝叶斯动态模型的适应性设计,用于在I/II期临床试验中的瘤学剂量优化
Yingjie Qiu1,2, Mingyue Li1
1Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Pharmaceutical statistics
|November 11, 2024
概括
项目Optimus旨在改革化疗剂量. 本研究介绍了瘤学试验的贝叶斯适应性设计,将毒性和疗效结合起来,以确定最佳剂量 (OD) 并改善药物开发.
科学领域:
- 瘤学 药物开发 药物开发
- 临床试验设计 临床试验设计
- 生物统计学 生物统计学
背景情况:
- 传统的"更多是更好的"化疗剂量模式已经过时,新的向疗法和抗体-药物联合体 (ADC) 已经过时.
- 美国食品和药物管理局 (FDA) 启动了"最佳项目",以解决瘤药物开发中的剂量优化和选择问题.
- 早期瘤学试验面临的挑战是由于数据的变化和刚性参数模型.
研究的目的:
- 开发一种新的自适应性临床试验设计,以优化早期瘤学研究中的剂量选择.
- 为了同时纳入毒性和疗效数据,以进行可靠的最佳剂量 (OD) 识别.
- 提高设计的适应性,以延迟毒性和疗效的结果.
主要方法:
- 利用贝叶斯动态模型,以最小的假设,利用不同剂量水平的信息.
- 采用贝叶斯模型的平均值来管理剂量反应关系中的不确定性.
- 在I/II期试验中开发了一种结合毒性和疗效的适应性设计,用于在I/II期试验中选择最佳剂量.
主要成果:
- 拟议的贝叶斯适应设计在各种模拟场景中展示了可取的操作特征.
- 该方法有效地整合了毒性和疗效数据,以进行可靠的最佳剂量识别.
- 该设计被证明可以适应涉及延迟毒性和疗效结果的场景.
结论:
- 建议的贝叶斯适应设计为瘤学药物开发中的最佳剂量选择提供了强大而灵活的方法.
- 这种方法解决了传统剂量模式的局限性,并支持了 Project Optimus 的目标.
- 该设计为I/II期瘤学试验提供了实际框架,如试验示例所示.
更多相关视频
相关概念视频
Nonlinear Pharmacokinetics: Overview
282
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
282
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
60
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
60
Analysis of Population Pharmacokinetic Data
235
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
235
Pharmacokinetic Models: Comparison and Selection Criterion
45
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
45
Structure-Activity Relationships and Drug Design
597
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
597


